Early understanding of diabetes risk could help in better disease management

Al­to Neu­ro­science has un­veiled topline da­ta from a mid-stage tri­al of its ma­jor de­pres­sive dis­or­der (MDD) drug can­di­date, which showed po­ten­tial in pa­tients with a

Ace­lyrin said Mon­day that its lead drug izok­ibep failed to meet the pri­ma­ry end­point in a Phase IIb/III tri­al in pa­tients with hidradeni­tis sup­pu­ra­ti­va —

In the lat­est de­vel­op­ment in the “high­ly dy­nam­ic” mol­e­c­u­lar glue space, Mer­ck KGaA has inked a dis­cov­ery agree­ment with C4 Ther­a­peu­tics for two pro­tein de­graders